Recordati S.p.A. - Publications

Print Page

Bookmark Page

Publications

Rosenthal T., Rosenmann E., Tomassoni D., Amenta F.
Effect of lercanidipine on kidney microanatomy in cohen-rosenthal diabetic hypertensive rats.
J. of Cardiovascular Pharmacology and Therapeutics Vol. 12 (2), pag. 145-52 (2007)
Barrios V., Escobar C., Navarro A., Calderon A., Ruilope L.M.
Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: the ELECTRA study.
Therapy Vol. 4 (4), pag. 433-440 (2007)
Barrios V., Escobar C., Navarro A., Echarri R., Barrios L., Navarro-Cid J., Calderon A.
Efectividad y tolerabilidad de lercanidipino en los pacientes hipertensos de alto riesgo. Datos del estudio LAURA.
Hipertension Vol. 24 (4), pag. 157-63 (2007)
Hair P.I., Scott L.J., Perry C.M.
Fixed-Dose combination Lercanidipine/Enalapril.
Drugs Vol. 67 (1), pag. 95-106 (2007)
Beckey C., Lundy A., Lutfi N.
Lercanidipine in the treatment of hypertension.
Annals of Pharmacotherapy Vol. 41 (3), pag. 465-73 (2007)
Agrawal R., Marx A., Haller H.
Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
J of Hypetrtension Vol. 24, pag. 185-192 (2006)
Martinez M.L.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B.T., Gerlach R.F., Tanus-Santos J.E.
Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension.
J. Cardiovasc. Pharmacol. Vol. 47, No. 1, pag. 117-122 (2006)
Borghi C.
Les patients hypertendus profitent d’une nouvelle génération d’antagonistes du calcium. La lercanidipine : efficacité équivalente avec moins d’effets indésirables.
Rev Med Suisse Vol. 2 (65), pag. 1266-7 (2006)
Barrios V., Escobar C., Navarro A., Barrios L., Navarro-Cid J., Calderon A.
Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study.
Int J Clin Pract Vol. 60 (11), pag. 1364-1370 (2006)
Venkata C. S.Ram
Hypertension, possible vascular protection and lercanidipine.
Expert Rev. Cardiovasc. Ther. Vol. 4 (6), pag. 783-788 (2006)
Luque M., Navarro A., Martell N.
Use of non-steroidal anti-inflammatory drugs does not modify the antihypertensive effect of lercanidipine in essential hypertension.
Br. J. Cardiol Vol. 13, Issue 5, pag. 353-59 (2006)
Barrios V., Escobar C., Calderon A., Navarro A., Ruilope L.M.
The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study.
Br. J. Cardiol Vol. 13, Issue 6, pag. 433-440 (2006)
Meier P., Burnier M.
La Lercanidipine, un inhibiteur calcique de troisième génération. Quels avantages ?.
Rev. Med. Suisse Vol. 2, pag. 2047-53 (2006)
Scholze J., Ney U., Herrmann D.
The treatment of obesity related hypertension with Lercanidipe – a double blind, placebo controlled trial.
Deutsche Medizinische Wochenschrift Vol. 131, pag. S147-S198 (2006)
Tisaire-Sanchez J., Roma J., Camacho-Azcargorta I., Bueno-Gomez J., Mora-Macia J., Navarro A.
Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.
Vascular Health and Risk Management Vol. 2 (4), pag. 491-498 (2006)
Borghi C., Prandin M.G., Costa F.V., Dormi A., Bacchelli S., Immordino V., Veronesi M., Ambrosioni E.
Compliance to antihypertensive treatment and monotherapy. Behaviour of the calcium-channel blocker lercanidipine.
J. of Hypertension Vol. 23, Suppl. 2, pag, S64 (2005)
Urbinelli R., Scart Gres C., Bassous M., Allaert F.
General practitioner opinions of the benefit of new long acting dihydropyridines Vs previous calcium channel blockers.
J. of Hypertension Vol. 23, Suppl. 2, pag. S412 (2005)
Allaert F., Causse C., Vernet N.
Reinduction rate with lercanidipine in patients who have stopped treatment with dihydropyridine because of lower limb oedema.
J. of Hypertension Vol. 23, Suppl. 2, pag. S70-71 (2005)
Janaviciene S., Laucevicius A., Subkovas E., Petrulioniene Z., Kibarskis A., Ryliskyte L.
Calcium antagonist lercanidipine improves endothelium-dependent vasodilatation of the brachial artery in patients with proved coronary vasospam.
Seminars in Cardiology Vol. 11, No, 1, pag. 15-23 (2005)
Borghi C.
Lercanidipine in hypertension.
Vascular Health and Risk Management Vol. 1(3), pag. 173-182 (2005)
Borghi C., Prandin M.G., Costa F.V., Dormi A., Bacchelli S., Immordino V., Veronesi M., Ambrosioni M.
Compliance of antihypertensive treatment and monotherapy. Behaviour of the calcium-channel blocker lercanidipine.
Am J Hypertension Vol. 18(5), pag. 51A (2005)
Kim M-K., Park C-H.
A randomized crossover study of the additive effect of lercanidipine and indapamide in patients with the mild to moderate hypertension.
Am J Hypertension Vol. 18(5), pag. 66A (2005)
Lefebvre J., Poirier L., Lacouciere Y.
Comparative effects of lercanidipine, amlodipine and hydrochlorothiazide on 24-hour ambulatory blood pressure and leg edema in confirmed ambulatory hypertensive patients.
Am J Hypertension Vol. 18(5), pag. 66-67A (2005)
Sonkusare S., Srinivasan K., Kaul C., Ramarao P.
Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats.
Life Sciences Vol. 77, pag. 1-14 (2005)
Efecto de asociar una dihidropiridina a la monoterapia antihipertensiva.
Martell Claros N., Navarro A., Luque M.
Hipertension Vol. 22 (1), pag. 15-20, 2005
Lercanidipine in patients with chronic renal failure: the ZAFRA Study.
Robles N.R., Ocon J., Gomez C.F., Manjon M., Pastor L., Herrera J., Villatoro J., Calls J., Torrijos J., Rodriguez V.I., Rodriguez M.M.A., Mendez M.L., Morey A., Martinez F.I., Marco J., Liebana A., Rincon B., Tornero F.
Renal Failure Vol. 1, pag. 73-80, 2005
Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G.
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria. DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina).
Diabetes, Nutrition & Metabolism Vol. 17: 259-266 (2004)
Acanfora D., Gheorghiade M., Trojano L., Furgi G., Papa A., Cacciatore F., Viati L., Mazzella F., Rengo F.
A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina.
American Journal of Therapeutics 11, 423-432 (2004)
Canavesi M., Baldini N., Leonardi A., Sironi G., Bellosta S., Bernini F.
In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages.
J Cardiovasc Pharmacol 2004; 44: 416-422
Matthew R. Weir
Matthew R. Weir Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance.
J Clin Hypertens. 2003; 5: 330-335
Robles N.R., Pastor L., Manjón M., Ocón J., Gómez Campderá F., Herrera J., Villatoro J., Calls J., Torrijos J., Rodríguez Villareal I., Rodríguez Martínez M.A., Méndez M.L., Morey A., Martínez Fernandez I., Marco J., Liebana A., Rincón B., Tornero F.
Lercanidipino en pacientes diabéticos con insuficiencia renal.
Nefrología 2004; Vol. XXIV. Número 4: 338-343
Luque M., Navarro A., Martell N.
NSAID do not modify the antihypertensive effect of the dihydropiridine lercanidipine.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S119
Martell N., Lopez-Eady M.D., Castro P., Mortoneda E., Luque M.
Modification of the pulse pressure in elderly hypertensives treated with lercanidipino.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S121
Barrios V., Calderon A., Navarro A., Noya C., Barrios L., Navarro-Cid J., Tomas J.P., Herranz I., Prieto L., Ruilope L.M.
Lercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The LAURA study.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S235
Marx A., Lichtenthal A., Milbredt C., Ott R., Tegeler S., Zegenhagen-Phiong B., Agrawal R.
Effect of antihypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S236
Barrios V., Calderon A., Navarro A., Noya C., Herranz I., Prieto L., Tomas J.P., Escobar C., Roldan C., Ruilope L.M.
Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S258
Mallion J.M., Allaert F.A., Scart-Gres C., Bassous S.
Variations in the frequency of lower limb oedema in patients receiving lercanidipine in adjunction to their antihypertensive treatment.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S269
Menne J., Park J.K., Lindschau C., Kielstein J.T., Mueller D., Kirsch T., Bahlmann F.H., Haller H., Fliser D.
Treatment with the calcium channel antagonist lercanidipine modulates asymmetric dimethylarginine (ADMA).
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S335
Menne J., Lindschau C., Park J.K., Mueller D., Bahlmann F.H., Kirsch T., Haller H., Fliser D.
The calcium channel antagonist lercanidipine reduces inflammation markers and prolongs survival.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S337
Poncelet P., Clerson P., Ribstein J., Bassous M., Scart Gres C.
Efficacy and safety of lercanidipine are not age-dependent. AGATE study.
Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S389
Poncelet P., Ribstein J., Goullard L., Bassous M., Scart Grès C., Clerson P.
Efficacité et tolérance de la lercanidipine ne sont pas liées à l'age des patients hypertendus: étude AGATE.
Annales de Cardiologie et d'Angéiologie 53 (2004) 123-130
Wirtz S., Herzig S.
Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine.
British Journal of Pharmacology (2004) 142, 275-284
Millar-Craig M., Shaffu B., Greenough A., Mitchell L., McDonald C.
Lercanidipine vs lacidipine in isolated systolic hypertension.
Journal of Human Hypertension (2003) 17, 799-806
Barrios Alonso V., Tomas Zarlenga J.P., Navarro Lima A., Esteras Sierra A., Luque Otero M., Romero Julia J., Tamargo Menendez J., Prieto Valiente L., Herranz Tejedor I., Navarro Cid J., Ruilope Urioste L.M.
Efectividad antihipertensiva y tolerabilidad de lercanidipino en diabeticos, en pacientes con hipertension sistolica aislada y en ancianos. Analisis de subgruops del estudio ELYPSE.
HIPERTENSION 2003; 20(8): 347-53
Bang L.M., Chapman T.M., Goa K.L.
Lercanidipine: a review of its efficacy in the management of hypertension.
DRUGS 2003: 63 (22): 2449-2472
Pedrinelli R., Dell'Omo G., Nuti M., Menegato A., Balbarini A., Mariani M.
Heterogeneous effect of calcium antagonists on leg oedema: a camparison of amlodipine versus lercanidipine in hypertensive patients.
Journal of Hypertension, 21 (2003) 1969-1973.
Cherubini A., Fabris F., Ferrari E., Cucinotta D., Antonelli Incalzi R., Senin U.
Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study.
Archives of Gerontology and Geriatrics 37 (2003) 203-212.
Romito R., Pansini M.I.,Perticone F., Antonelli G., Pitzalis M., Rizzon P.
Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the LErcanidipine in ADults (LEAD) study.
Journal of Clinical Hypertension Jul-Aug 2003, 5(4) p249-53.
Fogari R., Mugellini A., Zoppi A., Corradi L., Rinaldi A., Derosa G., Preti P.
Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension.
American Journal of Hypertension 2003; 16(7): 596-9
Abellan Aleman J., Martinez Garcia J.F., Merino Sanchez J., Gil Guillen V., Latorre Hernandez J., Divison Garrote J.A., Fernandez Torres C., Fernandez Montero F., Navarro Lima A.
Valoracion de la semiologia psicosomatica en hipertensos tratados con lercanidipino (estudio LERCAPSICO)
Anales de Medicina Interna 2003 ; 20(6): 287-291
Robles N.R., Canelada J.A., Iglesias M., Angulo E., Lopez Acedo A., Diaz Olea E., Cidoncha F., Guerras M., Fuentes J., Garrido J., Lapie J., Pena J., Aguilar A., Hidalgo P.
Evaluacion del lercanidipino en atencion primaria: seguridad y eficacia. Resultados del estudio LAPSE.
Anales de Medicina Interna 2003 ; 20(6): 282-286
Amenta F., Peleg E., Tomassoni D., Sabbatini M., Rosenthal T.
Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats.
Hypertension 2003 ; 41(6): 1330-5
Borghi C., Prandin M.G., Dormi A., Ambrosioni E.
Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the Lercanidipine Challenge Trial.
Blood Pressure 2003: 12: (Suppl.1) 14-21
Massicotte J., Viens A., Yao MH., Leonardi A., Sironi G., Wang H., Dumont L.
Effects of lercanidipine on coronary reactivity and myocardial remodeling in transition to heart failure in cardiomyopathic hamsters.
Acta Pharmacologica Sinica 2003; 24(3): 199-206
Tomassoni D., Sabbatini M., Amenta F.
Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats.
Journal of Cardiovascular Pharmacology 2003; 41 (4), 544-52
Johansen P.L., Stranden E., Helberg S., Wessel-Aas T., Risberg K., Ronnevik P.K., Istad H., Madsbu S.
Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.
Journal of Hypertension 2003; 21(5): 1003-1010
Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti G., Magagna A., Salvetti A.
Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension.
Hypertension 2003; 41: 950-955
Grassi G., Seravalle G., Turri C., Bolla GB, Mancia G.
Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension.
Hypertension 2003; 41: 558-562
Frishman W.H.
Are antihypertensive agents protective against dementia? A review of clinical and preclinical data.
Heart Disease 2002; Vol. 4: 380-386
Schwinger R.H.G., Schmidt-Mertens A.
The new lipophilic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects.
Dtsch Med Wochenschr 2002; Vol. 127 (Suppl. 1): S13
Messerli F.H.
Vasodilatory edema: a common side effect of antihypertensive therapy.
Current Cardiology Reports 2002; Vol. 4: 479-482
Leonetti G., Magnani B., Pessina AC, Rappelli A., Trimarco B., Zanchetti A.
Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
American Journal of Hypertension 2002; Vol. 15, No.11: 932-940
Rachmani R., Levi Z., Zadoc BS, Ravid M.
Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
Clinical Pharmacology & Therapeutics 2002; 72: 302-7.
Acanfora D., Trojano L., Gheorghiade M., Picone C., Papa A., Furgi G., Giuliano F., Maestri R., Rengo F.
A randomised, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina; effects on myocardial ischemia and heart rate variablity"
American Journal of Therapeutics 2002; 9: 444-453.
Sabbatini M, Tomassoni D, Di Tullio MA, Amenta F
Neuroprotective effect of treatment with calcium antagonists on hypertensive retina.
Clinical and Experimental Hypertension Vol.24, Nos. 7&8, pp. 727-740, 2002
James IGV, Jones A, Davies P
A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension.
Journal of Human Hypertension (2002) 16, 605-610
Messerli FH
Calcium antagonists in hypertension: from hemodynamics to outcomes.
American Journal of Hypertension Vol.15 (7 pt 2), 94S-97S; 2002
Viviani GL
Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension.
Journal Cardiovascular Pharmacology 2002 Jul; 40(1): 133-9
Ravassa S., Ardanaz N., Lopez B., Gonzalez A., Muniz P., Diez J.
Involvement of cardiotrophin-1 signaling pathway in cardiac apoptosis of spontaneously hypertensive rats.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S30
Kanda T., Hayashi K., Ozawa Y., Nagahama T., Homma K., Tokuyama H., Okubo K., Takamatsu I., Saruta T.
Role of T-type calcium channels as a determinant of glomerular microcirculation and subsequent renal protection.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S48
Calvo C., Hermida RC., Navarro A.
Treatment of elderly hypertensive patients. Preliminary results from the ZANYCAL study.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S80
Herrera J., Ghais Z., Gonzalez L.
Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S162
Motero J., Marques E., Eugenio JM, Mora F., Hinojosa JL, Santos F., Aragon J., Aquado A., Del Rio C.
Comparative study of the antihypertensive efficacy of lercanidipine in the treatment of mild to moderate high blood pressure in patients under and over 65 years old.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S162
Luque M., Ruilope LM., Tamargo J., Navarro A.
Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S163
Seravalle G., Stella ML, Foglia G., Quarti F., Facchini A., Grassi G., Mancia G.
Temporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S190
Versari D., Virdis A., Ghiadoni L., Magagna A., Taddei S., Salvetti A.
Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S270
Barrios V., Prieto L., Suarez C., Herranz I., Ruilope LM
Treatment compliance with lercanidipine: ELECTRA study.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S243
Robles NR, Vilatoro J., Pastor L., Manjon M., Ocon J., Gomez Campdera F.
Lercanidipie in chronic renal failure.
Journal of Hypertension 2002, Vol. 20(suppl. 4), S391
Kalus JS, White CM
Lercanidipine: a long-acting dihydropyridine calcium channel blocker for treatment of hypertension.
Formulary Vol.37(5), 234-238; 2002
Barrios V., Carrasco J.L., Esteras A., Herranz I., Luque M., Navarro A., Navarro-Cid J., Prieto L., Romero J., Ruilope L.M., Tamargo J.
Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study.
Blood Pressure Vol. 11, pg. 95-100 (2002)
Fogari R., Corradi L., Mugellini A., Preti P.
Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension.
American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 36/A (2002)
Seravalle G., Stella M.L., Grassi G., Mancia G.
Comparative effects of lercanidipine and hydrochlorothiazide on hypertension-related cardiac and vascular structural alterations.
American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 39/A (2002)
Versari D., Virdis A., Ghiadoni L., Magagna A., Taddei S., Salvetti A.
Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients.
American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 42/A (2002)
Barrios V., Prieto L., Herranz I., Suarez C., Ruilope L.M.
Treatment compliance with lercanidipine, ELECTRA study.
American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 50/A (2002)
Crippa G., Venturi C., Carrara G.
Effect of antihypertensive treatment with carvedilol or lercanidipine on ambulatory blood pressure variability.
American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 50/A (2002)
Pedrinelli R., Menegato A., Nuti M., Dell'Omo G., Balbarini A., Mariani M.
Dihydropyridine calcium channel blockers and dependent edema: a comparison between amlodipine and lercanidipine in essential hypertensive patients.
American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 54/A (2002)
Hollenberg N.K.
Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials.
American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 58-59/A (2002)
Calvo C., Hermida R.C., Navarro A.
Treatment of elderly hypertensive patients. Preliminary results from the ZANYCAL study.
American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 110/A (2002)
Zanchetti A.
Efficacy and tolerability of lercanidipine in elderly hypertensives: results of a multicenter, double-blind, randomized study.
American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 117/A (2002)
Ravassa S., Ardanaz N., Muniz P., Gonzalez A., Lopez B., Diez J., Fortuno M.A.
Association between a deficient cardiotrophin-1 signaling pathway and cardiac apoptosis in genetic hypertension.
American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 148/A (2002)
Amenta F., Leonardi A., Sabbatini M., Testa R., Tomassoni D., Vitaioli L.
Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats.
Journal Cardiovascular Pharmacology Vol.39(1), pg.39-48 (2002)
Venkata C.S. Ram
Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension.
The American Journal of Cardiology Vol. 89, pg. 214-15 (2002)
Hair P.I., Scott L.J., Perry C.M.
Fixed-Dose combination Lercanidipine/Enalapril.
Drugs Vol. 67 (1), pag. 95-106 (2007)
Beckey C., Lundy A., Lutfi N.
Lercanidipine in the treatment of hypertension.
Annals of Pharmacotherapy Vol. 41 (3), pag. 465-73 (2007)
Agrawal R., Marx A., Haller H.
Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
J of Hypetrtension Vol. 24, pag. 185-192 (2006)
Martinez M.L.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B.T., Gerlach R.F., Tanus-Santos J.E.
Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension.
J. Cardiovasc. Pharmacol. Vol. 47, No. 1, pag. 117-122 (2006)
Borghi C.
Les patients hypertendus profitent d’une nouvelle génération d’antagonistes du calcium. La lercanidipine : efficacité équivalente avec moins d’effets indésirables.
Rev Med Suisse Vol. 2 (65), pag. 1266-7 (2006)
Barrios V., Escobar C., Navarro A., Barrios L., Navarro-Cid J., Calderon A.
Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study.
Int J Clin Pract Vol. 60 (11), pag. 1364-1370 (2006)
Venkata C. S.Ram
Hypertension, possible vascular protection and lercanidipine.
Expert Rev. Cardiovasc. Ther. Vol. 4 (6), pag. 783-788 (2006)
Luque M., Navarro A., Martell N.
Use of non-steroidal anti-inflammatory drugs does not modify the antihypertensive effect of lercanidipine in essential hypertension.
Br. J. Cardiol Vol. 13, Issue 5, pag. 353-59 (2006)
Barrios V., Escobar C., Calderon A., Navarro A., Ruilope L.M.
The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study.
Br. J. Cardiol Vol. 13, Issue 6, pag. 433-440 (2006)
Meier P., Burnier M.
La Lercanidipine, un inhibiteur calcique de troisième génération. Quels avantages ?.
Rev. Med. Suisse Vol. 2, pag. 2047-53 (2006)
Scholze J., Ney U., Herrmann D.
The treatment of obesity related hypertension with Lercanidipe – a double blind, placebo controlled trial.
Deutsche Medizinische Wochenschrift Vol. 131, pag. S147-S198 (2006)
Tisaire-Sanchez J., Roma J., Camacho-Azcargorta I., Bueno-Gomez J., Mora-Macia J., Navarro A.
Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.
Vascular Health and Risk Management Vol. 2 (4), pag. 491-498 (2006)

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Publications Print Page Bookmark Page
	Publications Rosenthal T., Rosenmann E., Tomassoni D., Amenta F. Effect of lercanidipine on kidney microanatomy in cohen-rosenthal diabetic hypertensive rats. J. of Cardiovascular Pharmacology and Therapeutics Vol. 12 (2), pag. 145-52 (2007) Barrios V., Escobar C., Navarro A., Calderon A., Ruilope L.M. Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: the ELECTRA study. Therapy Vol. 4 (4), pag. 433-440 (2007) Barrios V., Escobar C., Navarro A., Echarri R., Barrios L., Navarro-Cid J., Calderon A. Efectividad y tolerabilidad de lercanidipino en los pacientes hipertensos de alto riesgo. Datos del estudio LAURA. Hipertension Vol. 24 (4), pag. 157-63 (2007) Hair P.I., Scott L.J., Perry C.M. Fixed-Dose combination Lercanidipine/Enalapril. Drugs Vol. 67 (1), pag. 95-106 (2007) Beckey C., Lundy A., Lutfi N. Lercanidipine in the treatment of hypertension. Annals of Pharmacotherapy Vol. 41 (3), pag. 465-73 (2007) Agrawal R., Marx A., Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J of Hypetrtension Vol. 24, pag. 185-192 (2006) Martinez M.L.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B.T., Gerlach R.F., Tanus-Santos J.E. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. Cardiovasc. Pharmacol. Vol. 47, No. 1, pag. 117-122 (2006) Borghi C. Les patients hypertendus profitent d’une nouvelle génération d’antagonistes du calcium. La lercanidipine : efficacité équivalente avec moins d’effets indésirables. Rev Med Suisse Vol. 2 (65), pag. 1266-7 (2006) Barrios V., Escobar C., Navarro A., Barrios L., Navarro-Cid J., Calderon A. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study. Int J Clin Pract Vol. 60 (11), pag. 1364-1370 (2006) Venkata C. S.Ram Hypertension, possible vascular protection and lercanidipine. Expert Rev. Cardiovasc. Ther. Vol. 4 (6), pag. 783-788 (2006) Luque M., Navarro A., Martell N. Use of non-steroidal anti-inflammatory drugs does not modify the antihypertensive effect of lercanidipine in essential hypertension. Br. J. Cardiol Vol. 13, Issue 5, pag. 353-59 (2006) Barrios V., Escobar C., Calderon A., Navarro A., Ruilope L.M. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study. Br. J. Cardiol Vol. 13, Issue 6, pag. 433-440 (2006) Meier P., Burnier M. La Lercanidipine, un inhibiteur calcique de troisième génération. Quels avantages ?. Rev. Med. Suisse Vol. 2, pag. 2047-53 (2006) Scholze J., Ney U., Herrmann D. The treatment of obesity related hypertension with Lercanidipe – a double blind, placebo controlled trial. Deutsche Medizinische Wochenschrift Vol. 131, pag. S147-S198 (2006) Tisaire-Sanchez J., Roma J., Camacho-Azcargorta I., Bueno-Gomez J., Mora-Macia J., Navarro A. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vascular Health and Risk Management Vol. 2 (4), pag. 491-498 (2006) Borghi C., Prandin M.G., Costa F.V., Dormi A., Bacchelli S., Immordino V., Veronesi M., Ambrosioni E. Compliance to antihypertensive treatment and monotherapy. Behaviour of the calcium-channel blocker lercanidipine. J. of Hypertension Vol. 23, Suppl. 2, pag, S64 (2005) Urbinelli R., Scart Gres C., Bassous M., Allaert F. General practitioner opinions of the benefit of new long acting dihydropyridines Vs previous calcium channel blockers. J. of Hypertension Vol. 23, Suppl. 2, pag. S412 (2005) Allaert F., Causse C., Vernet N. Reinduction rate with lercanidipine in patients who have stopped treatment with dihydropyridine because of lower limb oedema. J. of Hypertension Vol. 23, Suppl. 2, pag. S70-71 (2005) Janaviciene S., Laucevicius A., Subkovas E., Petrulioniene Z., Kibarskis A., Ryliskyte L. Calcium antagonist lercanidipine improves endothelium-dependent vasodilatation of the brachial artery in patients with proved coronary vasospam. Seminars in Cardiology Vol. 11, No, 1, pag. 15-23 (2005) Borghi C. Lercanidipine in hypertension. Vascular Health and Risk Management Vol. 1(3), pag. 173-182 (2005) Borghi C., Prandin M.G., Costa F.V., Dormi A., Bacchelli S., Immordino V., Veronesi M., Ambrosioni M. Compliance of antihypertensive treatment and monotherapy. Behaviour of the calcium-channel blocker lercanidipine. Am J Hypertension Vol. 18(5), pag. 51A (2005) Kim M-K., Park C-H. A randomized crossover study of the additive effect of lercanidipine and indapamide in patients with the mild to moderate hypertension. Am J Hypertension Vol. 18(5), pag. 66A (2005) Lefebvre J., Poirier L., Lacouciere Y. Comparative effects of lercanidipine, amlodipine and hydrochlorothiazide on 24-hour ambulatory blood pressure and leg edema in confirmed ambulatory hypertensive patients. Am J Hypertension Vol. 18(5), pag. 66-67A (2005) Sonkusare S., Srinivasan K., Kaul C., Ramarao P. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sciences Vol. 77, pag. 1-14 (2005) Efecto de asociar una dihidropiridina a la monoterapia antihipertensiva. Martell Claros N., Navarro A., Luque M. Hipertension Vol. 22 (1), pag. 15-20, 2005 Lercanidipine in patients with chronic renal failure: the ZAFRA Study. Robles N.R., Ocon J., Gomez C.F., Manjon M., Pastor L., Herrera J., Villatoro J., Calls J., Torrijos J., Rodriguez V.I., Rodriguez M.M.A., Mendez M.L., Morey A., Martinez F.I., Marco J., Liebana A., Rincon B., Tornero F. Renal Failure Vol. 1, pag. 73-80, 2005 Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria. DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diabetes, Nutrition & Metabolism Vol. 17: 259-266 (2004) Acanfora D., Gheorghiade M., Trojano L., Furgi G., Papa A., Cacciatore F., Viati L., Mazzella F., Rengo F. A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina. American Journal of Therapeutics 11, 423-432 (2004) Canavesi M., Baldini N., Leonardi A., Sironi G., Bellosta S., Bernini F. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol 2004; 44: 416-422 Matthew R. Weir Matthew R. Weir Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens. 2003; 5: 330-335 Robles N.R., Pastor L., Manjón M., Ocón J., Gómez Campderá F., Herrera J., Villatoro J., Calls J., Torrijos J., Rodríguez Villareal I., Rodríguez Martínez M.A., Méndez M.L., Morey A., Martínez Fernandez I., Marco J., Liebana A., Rincón B., Tornero F. Lercanidipino en pacientes diabéticos con insuficiencia renal. Nefrología 2004; Vol. XXIV. Número 4: 338-343 Luque M., Navarro A., Martell N. NSAID do not modify the antihypertensive effect of the dihydropiridine lercanidipine. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S119 Martell N., Lopez-Eady M.D., Castro P., Mortoneda E., Luque M. Modification of the pulse pressure in elderly hypertensives treated with lercanidipino. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S121 Barrios V., Calderon A., Navarro A., Noya C., Barrios L., Navarro-Cid J., Tomas J.P., Herranz I., Prieto L., Ruilope L.M. Lercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The LAURA study. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S235 Marx A., Lichtenthal A., Milbredt C., Ott R., Tegeler S., Zegenhagen-Phiong B., Agrawal R. Effect of antihypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S236 Barrios V., Calderon A., Navarro A., Noya C., Herranz I., Prieto L., Tomas J.P., Escobar C., Roldan C., Ruilope L.M. Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S258 Mallion J.M., Allaert F.A., Scart-Gres C., Bassous S. Variations in the frequency of lower limb oedema in patients receiving lercanidipine in adjunction to their antihypertensive treatment. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S269 Menne J., Park J.K., Lindschau C., Kielstein J.T., Mueller D., Kirsch T., Bahlmann F.H., Haller H., Fliser D. Treatment with the calcium channel antagonist lercanidipine modulates asymmetric dimethylarginine (ADMA). Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S335 Menne J., Lindschau C., Park J.K., Mueller D., Bahlmann F.H., Kirsch T., Haller H., Fliser D. The calcium channel antagonist lercanidipine reduces inflammation markers and prolongs survival. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S337 Poncelet P., Clerson P., Ribstein J., Bassous M., Scart Gres C. Efficacy and safety of lercanidipine are not age-dependent. AGATE study. Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S389 Poncelet P., Ribstein J., Goullard L., Bassous M., Scart Grès C., Clerson P. Efficacité et tolérance de la lercanidipine ne sont pas liées à l'age des patients hypertendus: étude AGATE. Annales de Cardiologie et d'Angéiologie 53 (2004) 123-130 Wirtz S., Herzig S. Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. British Journal of Pharmacology (2004) 142, 275-284 Millar-Craig M., Shaffu B., Greenough A., Mitchell L., McDonald C. Lercanidipine vs lacidipine in isolated systolic hypertension. Journal of Human Hypertension (2003) 17, 799-806 Barrios Alonso V., Tomas Zarlenga J.P., Navarro Lima A., Esteras Sierra A., Luque Otero M., Romero Julia J., Tamargo Menendez J., Prieto Valiente L., Herranz Tejedor I., Navarro Cid J., Ruilope Urioste L.M. Efectividad antihipertensiva y tolerabilidad de lercanidipino en diabeticos, en pacientes con hipertension sistolica aislada y en ancianos. Analisis de subgruops del estudio ELYPSE. HIPERTENSION 2003; 20(8): 347-53 Bang L.M., Chapman T.M., Goa K.L. Lercanidipine: a review of its efficacy in the management of hypertension. DRUGS 2003: 63 (22): 2449-2472 Pedrinelli R., Dell'Omo G., Nuti M., Menegato A., Balbarini A., Mariani M. Heterogeneous effect of calcium antagonists on leg oedema: a camparison of amlodipine versus lercanidipine in hypertensive patients. Journal of Hypertension, 21 (2003) 1969-1973. Cherubini A., Fabris F., Ferrari E., Cucinotta D., Antonelli Incalzi R., Senin U. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Archives of Gerontology and Geriatrics 37 (2003) 203-212. Romito R., Pansini M.I.,Perticone F., Antonelli G., Pitzalis M., Rizzon P. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the LErcanidipine in ADults (LEAD) study. Journal of Clinical Hypertension Jul-Aug 2003, 5(4) p249-53. Fogari R., Mugellini A., Zoppi A., Corradi L., Rinaldi A., Derosa G., Preti P. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. American Journal of Hypertension 2003; 16(7): 596-9 Abellan Aleman J., Martinez Garcia J.F., Merino Sanchez J., Gil Guillen V., Latorre Hernandez J., Divison Garrote J.A., Fernandez Torres C., Fernandez Montero F., Navarro Lima A. Valoracion de la semiologia psicosomatica en hipertensos tratados con lercanidipino (estudio LERCAPSICO) Anales de Medicina Interna 2003 ; 20(6): 287-291 Robles N.R., Canelada J.A., Iglesias M., Angulo E., Lopez Acedo A., Diaz Olea E., Cidoncha F., Guerras M., Fuentes J., Garrido J., Lapie J., Pena J., Aguilar A., Hidalgo P. Evaluacion del lercanidipino en atencion primaria: seguridad y eficacia. Resultados del estudio LAPSE. Anales de Medicina Interna 2003 ; 20(6): 282-286 Amenta F., Peleg E., Tomassoni D., Sabbatini M., Rosenthal T. Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats. Hypertension 2003 ; 41(6): 1330-5 Borghi C., Prandin M.G., Dormi A., Ambrosioni E. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the Lercanidipine Challenge Trial. Blood Pressure 2003: 12: (Suppl.1) 14-21 Massicotte J., Viens A., Yao MH., Leonardi A., Sironi G., Wang H., Dumont L. Effects of lercanidipine on coronary reactivity and myocardial remodeling in transition to heart failure in cardiomyopathic hamsters. Acta Pharmacologica Sinica 2003; 24(3): 199-206 Tomassoni D., Sabbatini M., Amenta F. Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology 2003; 41 (4), 544-52 Johansen P.L., Stranden E., Helberg S., Wessel-Aas T., Risberg K., Ronnevik P.K., Istad H., Madsbu S. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. Journal of Hypertension 2003; 21(5): 1003-1010 Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti G., Magagna A., Salvetti A. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41: 950-955 Grassi G., Seravalle G., Turri C., Bolla GB, Mancia G. Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41: 558-562 Frishman W.H. Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Disease 2002; Vol. 4: 380-386 Schwinger R.H.G., Schmidt-Mertens A. The new lipophilic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects. Dtsch Med Wochenschr 2002; Vol. 127 (Suppl. 1): S13 Messerli F.H. Vasodilatory edema: a common side effect of antihypertensive therapy. Current Cardiology Reports 2002; Vol. 4: 479-482 Leonetti G., Magnani B., Pessina AC, Rappelli A., Trimarco B., Zanchetti A. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. American Journal of Hypertension 2002; Vol. 15, No.11: 932-940 Rachmani R., Levi Z., Zadoc BS, Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clinical Pharmacology & Therapeutics 2002; 72: 302-7. Acanfora D., Trojano L., Gheorghiade M., Picone C., Papa A., Furgi G., Giuliano F., Maestri R., Rengo F. A randomised, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina; effects on myocardial ischemia and heart rate variablity" American Journal of Therapeutics 2002; 9: 444-453. Sabbatini M, Tomassoni D, Di Tullio MA, Amenta F Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clinical and Experimental Hypertension Vol.24, Nos. 7&8, pp. 727-740, 2002 James IGV, Jones A, Davies P A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. Journal of Human Hypertension (2002) 16, 605-610 Messerli FH Calcium antagonists in hypertension: from hemodynamics to outcomes. American Journal of Hypertension Vol.15 (7 pt 2), 94S-97S; 2002 Viviani GL Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. Journal Cardiovascular Pharmacology 2002 Jul; 40(1): 133-9 Ravassa S., Ardanaz N., Lopez B., Gonzalez A., Muniz P., Diez J. Involvement of cardiotrophin-1 signaling pathway in cardiac apoptosis of spontaneously hypertensive rats. Journal of Hypertension 2002, Vol. 20(suppl. 4), S30 Kanda T., Hayashi K., Ozawa Y., Nagahama T., Homma K., Tokuyama H., Okubo K., Takamatsu I., Saruta T. Role of T-type calcium channels as a determinant of glomerular microcirculation and subsequent renal protection. Journal of Hypertension 2002, Vol. 20(suppl. 4), S48 Calvo C., Hermida RC., Navarro A. Treatment of elderly hypertensive patients. Preliminary results from the ZANYCAL study. Journal of Hypertension 2002, Vol. 20(suppl. 4), S80 Herrera J., Ghais Z., Gonzalez L. Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting. Journal of Hypertension 2002, Vol. 20(suppl. 4), S162 Motero J., Marques E., Eugenio JM, Mora F., Hinojosa JL, Santos F., Aragon J., Aquado A., Del Rio C. Comparative study of the antihypertensive efficacy of lercanidipine in the treatment of mild to moderate high blood pressure in patients under and over 65 years old. Journal of Hypertension 2002, Vol. 20(suppl. 4), S162 Luque M., Ruilope LM., Tamargo J., Navarro A. Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study. Journal of Hypertension 2002, Vol. 20(suppl. 4), S163 Seravalle G., Stella ML, Foglia G., Quarti F., Facchini A., Grassi G., Mancia G. Temporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension. Journal of Hypertension 2002, Vol. 20(suppl. 4), S190 Versari D., Virdis A., Ghiadoni L., Magagna A., Taddei S., Salvetti A. Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients. Journal of Hypertension 2002, Vol. 20(suppl. 4), S270 Barrios V., Prieto L., Suarez C., Herranz I., Ruilope LM Treatment compliance with lercanidipine: ELECTRA study. Journal of Hypertension 2002, Vol. 20(suppl. 4), S243 Robles NR, Vilatoro J., Pastor L., Manjon M., Ocon J., Gomez Campdera F. Lercanidipie in chronic renal failure. Journal of Hypertension 2002, Vol. 20(suppl. 4), S391 Kalus JS, White CM Lercanidipine: a long-acting dihydropyridine calcium channel blocker for treatment of hypertension. Formulary Vol.37(5), 234-238; 2002 Barrios V., Carrasco J.L., Esteras A., Herranz I., Luque M., Navarro A., Navarro-Cid J., Prieto L., Romero J., Ruilope L.M., Tamargo J. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Pressure Vol. 11, pg. 95-100 (2002) Fogari R., Corradi L., Mugellini A., Preti P. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 36/A (2002) Seravalle G., Stella M.L., Grassi G., Mancia G. Comparative effects of lercanidipine and hydrochlorothiazide on hypertension-related cardiac and vascular structural alterations. American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 39/A (2002) Versari D., Virdis A., Ghiadoni L., Magagna A., Taddei S., Salvetti A. Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients. American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 42/A (2002) Barrios V., Prieto L., Herranz I., Suarez C., Ruilope L.M. Treatment compliance with lercanidipine, ELECTRA study. American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 50/A (2002) Crippa G., Venturi C., Carrara G. Effect of antihypertensive treatment with carvedilol or lercanidipine on ambulatory blood pressure variability. American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 50/A (2002) Pedrinelli R., Menegato A., Nuti M., Dell'Omo G., Balbarini A., Mariani M. Dihydropyridine calcium channel blockers and dependent edema: a comparison between amlodipine and lercanidipine in essential hypertensive patients. American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 54/A (2002) Hollenberg N.K. Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials. American J. Hypertension Vol. 15, (4) (Part 2/2), pg. 58-59/A (2002) Calvo C., Hermida R.C., Navarro A. Treatment of elderly hypertensive patients. Preliminary results from the ZANYCAL study. American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 110/A (2002) Zanchetti A. Efficacy and tolerability of lercanidipine in elderly hypertensives: results of a multicenter, double-blind, randomized study. American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 117/A (2002) Ravassa S., Ardanaz N., Muniz P., Gonzalez A., Lopez B., Diez J., Fortuno M.A. Association between a deficient cardiotrophin-1 signaling pathway and cardiac apoptosis in genetic hypertension. American J. Hypertension Vol. 15, (4) (Part 2/2) , pg. 148/A (2002) Amenta F., Leonardi A., Sabbatini M., Testa R., Tomassoni D., Vitaioli L. Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. Journal Cardiovascular Pharmacology Vol.39(1), pg.39-48 (2002) Venkata C.S. Ram Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension. The American Journal of Cardiology Vol. 89, pg. 214-15 (2002) Hair P.I., Scott L.J., Perry C.M. Fixed-Dose combination Lercanidipine/Enalapril. Drugs Vol. 67 (1), pag. 95-106 (2007) Beckey C., Lundy A., Lutfi N. Lercanidipine in the treatment of hypertension. Annals of Pharmacotherapy Vol. 41 (3), pag. 465-73 (2007) Agrawal R., Marx A., Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J of Hypetrtension Vol. 24, pag. 185-192 (2006) Martinez M.L.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B.T., Gerlach R.F., Tanus-Santos J.E. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. Cardiovasc. Pharmacol. Vol. 47, No. 1, pag. 117-122 (2006) Borghi C. Les patients hypertendus profitent d’une nouvelle génération d’antagonistes du calcium. La lercanidipine : efficacité équivalente avec moins d’effets indésirables. Rev Med Suisse Vol. 2 (65), pag. 1266-7 (2006) Barrios V., Escobar C., Navarro A., Barrios L., Navarro-Cid J., Calderon A. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study. Int J Clin Pract Vol. 60 (11), pag. 1364-1370 (2006) Venkata C. S.Ram Hypertension, possible vascular protection and lercanidipine. Expert Rev. Cardiovasc. Ther. Vol. 4 (6), pag. 783-788 (2006) Luque M., Navarro A., Martell N. Use of non-steroidal anti-inflammatory drugs does not modify the antihypertensive effect of lercanidipine in essential hypertension. Br. J. Cardiol Vol. 13, Issue 5, pag. 353-59 (2006) Barrios V., Escobar C., Calderon A., Navarro A., Ruilope L.M. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study. Br. J. Cardiol Vol. 13, Issue 6, pag. 433-440 (2006) Meier P., Burnier M. La Lercanidipine, un inhibiteur calcique de troisième génération. Quels avantages ?. Rev. Med. Suisse Vol. 2, pag. 2047-53 (2006) Scholze J., Ney U., Herrmann D. The treatment of obesity related hypertension with Lercanidipe – a double blind, placebo controlled trial. Deutsche Medizinische Wochenschrift Vol. 131, pag. S147-S198 (2006) Tisaire-Sanchez J., Roma J., Camacho-Azcargorta I., Bueno-Gomez J., Mora-Macia J., Navarro A. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vascular Health and Risk Management Vol. 2 (4), pag. 491-498 (2006)